Insmed (INSM) Stock Soars Following Positive Clinical Trial Data
Insmed Incorporated (NASDAQ: INSM) had a significant rise in shares due to positive outcomes from a clinical trial. The previous session had a 118.45% increase in INSM shares, closing at $48.06. Clinical Trial Achievement Insmed (INSM) revealed encouraging topline findings from the worldwide Phase 3 trial, the ASPEN study, which was randomized, double-blind, and placebo-controlled. […]
